Genelux Data Show Olvi-Vec Induces CD8+ T-Cell Influx and Platinum Resensitization
GNLX•Translational analysis from the Phase 1b/2 VIRO-15 trial shows Olvi-Vec primed immunochemotherapy induces a CD8+ T-cell influx and gene expression changes linked to platinum resensitization in pretreated ovarian cancer patients. These mechanistic data support reported progression-free survival in PRROC and bolster the rationale for the registrational Phase 3 OnPrime/GOG-3076 study.
1. Publication of Translational Findings
Genelux announced publication of translational and clinical analyses from its Phase 1b/2 VIRO-15 trial evaluating Olvi-Vec-primed immunochemotherapy in platinum-resistant/refractory ovarian cancer. The data appear in a peer-reviewed journal and detail biological effects of Olvi-Vec on tumor tissues from heavily pretreated patients.
2. Mechanistic Insights
Analyses revealed Olvi-Vec treatment leads to a marked influx of CD8+ tumor-infiltrating lymphocytes, direct viral infection and cytolysis of tumor cells, and coordinated gene expression changes associated with immune activation and enhanced sensitivity to subsequent platinum chemotherapy.
3. Clinical Implications
These mechanistic findings provide biological support for previously reported improvements in progression-free survival in PRROC patients and strengthen the rationale for the ongoing registrational Phase 3 OnPrime/GOG-3076 study of intraperitoneal Olvi-Vec combined with platinum-doublet and bevacizumab.
